According to a new study, modification of the immune system of a patient with heart failure, cuts down the risk of the patients death and the need for hospitalisation.
The study, led by Dr. Guillermo Torre-Amione, cardiologist at the Methodist DeBakey Heart Centre in Houston, stated that immune modulation therapy could provide a new way of treatment for patients with heart failure.
Immune modulation therapy could provide physicians with a new way of treating large numbers of patients with heart failure, said Torre.
The activation of the immune system in patients with systolic heart failure boosts the concentration of molecules, which can injure the heart in a way that leads to heart failure.
The finding reveals that modification of this immune response is an appealing potential therapy for many patients with heart failure.
The technique involves intentionally damaging some of the patients blood cells to trick the body into producing anti-inflammatory cells, which heal the damaged heart.
While further research is needed, the ability to change or modulate the patients immune response has now been shown to be attainable as well as successful in treating certain stages of heart failure, the Lancet quoted Torre, as saying.
In the study, the research team conducted a double-blind, placebo-controlled study of a device-based IMT on 2,246 patients.
All the patients had New York Heart Association (NYHA) functional class II-IV chronic heart failure, left ventricular systolic dysfunction, and hospitalisation for heart failure or intravenous drug therapy in an outpatient setting within the past 12 months.